CTAB assisted synthesis of MnFe2O4@ SiO2 nanoparticles for magnetic hyperthermia and MRI application. (June 2022)

• Record Type: Journal Article
• Authors: Kavkhani, Roya; Hajalilou, Abdollah; Abouzari-Lotf, Ebrahim; Ferreira, Liliana P.; Cruz, Maria Margarida; Yusefi, Mostafa; Parvini, Elahe; Ogholbeyg, Alireza Bali; Ismail, Umi Nabilah
• Is Part Of: Materials today communications. Volume 31(2022)
• Publication Date: 2022-06
• Subjects: Ferrite nanoparticles -- Hyperthermia -- Cytotoxicity -- Core-shell -- DAPI; Materials science -- Periodicals; 620.11
• DOI: 10.1016/j.mtcomm.2022.103412
• Languages: English
• ISSNs: 2352-4928

Abstract

Abstract: Magnetic fluid hyperthermia (MFH) has been proven as a promising cancer therapeutic approach in conjunction with chemotherapy or physiotherapy in patients. The research to find innovative materials with a higher specific absorption rate (SAR) to reduce the dose of magnetic nanoparticles in tumor treatment through MFH while being also adequate for Magnetic Resonance Imaging (MRI) is important. Herein, MnFe2 O4 NPs were synthesized with different sizes, using NaOH or NH4 OH as a reducing agent, via a green-assisted hydrothermal route. A tetraethyl orthosilicate with the assist of cetrimonium bromide was used to fabricate SiO2 @MnFe2 O4 NPs. Based on the Mössbauer and XRD results an undesired amount of α -Fe2 O3 was found in the samples synthesized with NH4 OH. Concentration-dependent cellular toxicity values were evaluated by invitro 3-(4, 5 dimethylthiazol-2-yl)−2, 5-diphenyltetrazolium bromide (MTT) assay on A549 cells, where bare and silica coated nanoparticles exhibited non-toxicity below 691 µg/mL and 566 µg/mL, respectively. The ability of bare MnFe2 O4 as the MRI contrast agent was higher compared to the silica-coated sample. The heating efficiency of the ferrofluids was recorded at 128 kHz and 10 kA/m and the highest SAR value was 39 W/g for the pristine MnFe2 O4 NPs, making them promising potential materials in MRI and cancer treatment. Graphical Abstract: ga1 Highlights: MnFe2 O4 NPs were synthesized via a hydrothermal route with two different reducing agents, NaOH and NH4 OH. The Mössbauer and XRD results revealed an undesired phase of hematite in α the samples synthesized with NH4 OH. The NPs were coated with high specific surface areas of SiO2 with the assistance of CTAB and TEOS. The ability of bare MnFe2 O4 NPs as the MRI contrast agent was higher compared to the silica-coated ones. The as-prepared ferrofluids can be used in medical applications as magnetic fluid hyperthermia (MFH).